Tetanus Clinical Trial
Official title:
Non-specific Effects of Vaccines - In Search of the Immunological Background
OBJECTIVES
- General: To investigate the immunological background for the non-specific effects of
diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality
- Specific: Examine the cytokine responses and possible association with morbidity in a
study of DTP vaccinated children who will be randomised to receive a measles vaccine or
no vaccine at 4½ months of age. (All children will receive a measles vaccine at 9
months of age)
Non-specific effects of vaccines The idea of vaccines having non-specific effects was first
proposed in 1991 from a study in Senegal, West Africa. It was discovered that children
receiving high-titre measles vaccine (HT) at 6 months of age had higher mortality than
children who received the standard titre measles vaccine (STD) at 9 months of age. The
difference was found only for girls. A study from Haiti confirmed the effect. Since children
vaccinated with HT had lower mortality than their equivalents who had not received any
measles vaccine, the difference in mortality between recipients of HT vaccine and STD
vaccine was explained by a non-specific beneficial effect of the STD measles vaccine rather
than a harmful effect of the HT vaccine. The non-specific beneficial effect of STD measles
vaccine on child mortality has been reconfirmed in many data-sets.
Also the BCG vaccine is associated with striking effects on child mortality reducing
mortality by about 50%. Further, among BCG vaccinated children, having a BCG scar or a
positive tuberculin reaction was associated with about 55% lower mortality in the following
12 months than among children who had a negative tuberculin reaction or who did not have a
BCG scar.
The effect of OPV is difficult to separate from the effects of BCG and DTP vaccines since
OPV is normally given together with these vaccines. There have, though, been some periods
without DTP in Bissau due to global shortage of vaccines, and we have compared the case
fatality at the hospital for children who received only OPV and children who received both
the prescribed OPV and DTP. Children having received OPV had 3-fold lower mortality than
children having received both vaccines. Data from an OPV vaccination campaign that took
place in Guinea-Bissau also suggested a non-specific beneficial effect for the recipients.
Further, studies from Chile and the Soviet Union have suggested that OPV had a beneficial
effect on mortality and morbidity.
In contrast, DTP, HBV and inactivated polio vaccine (IPV) seem to exert a non-specific
detrimental effect on child mortality, although the findings on DTP were considered
controversial by a recent review. Current studies indicate that the negative effect of DTP
may be neutralized by a subsequent measles vaccination. It is striking that all the vaccines
with a non-specific beneficial effect are live, whereas the vaccines with an apparently
harmful effect are killed. Results from animal studies have shown that attenuated live
vaccines tend to induce a Th1 response and offer better protection against severe disease
than the corresponding inactivated vaccines, which tend to induce a Th2 response. So far,
very few studies have examined whether these effects differ between male and female animals.
One study reported that BCG-vaccinated female mice were better protected against malaria
parasites than male mice (31). There is therefore an urgent need to conduct studies that can
help uncover the immunology behind the non-specific effects.
Sex-specific effects All epidemiological studies carried out so far confirms the observation
that non-specific effects are sex-specific. Live vaccines (measles, BCG, OPV) have a
beneficial effect that is particularly good for girls whereas inactivated vaccines (DTP,
HBV, IPV) have a negative effect for girls. To date, there are no immunological studies
which have examined whether routine vaccines affect the immune system differently for boys
and girls.
We thus propose to study, in a randomised controlled trial of measles vaccination taking
place in Guinea-Bissau, the immunology of non-specific effects of vaccination, and their
interaction with sex. Specifically, among children who have received the 3 recommended doses
of DTP, we will be able to compare the cytokine and antibody profiles of children who
receive an early dose of measles vaccine at 4½ months of age with children who receive no
additional vaccine at this age.
;
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
Completed |
NCT01689324 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
Completed |
NCT00804284 -
Database Surveillance Safety Study of PENTACEL® Vaccine
|
N/A | |
Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
Completed |
NCT00514709 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
|
Phase 3 | |
Completed |
NCT00379977 -
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
|
Phase 3 | |
Completed |
NCT00772369 -
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
|
Phase 4 | |
Completed |
NCT00879827 -
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
|
Phase 3 | |
Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
Completed |
NCT01267058 -
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
Recruiting |
NCT06049940 -
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
|
Phase 3 | |
Completed |
NCT00385255 -
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
|
Phase 3 |